Share Dominos Pizza now in terms of PE among most expensive food & drug retailers

The American stock Dominos Pizza trades with one the highest CAPE-ratios of the food & drug retailers. Currently the share is now traded at 185 times the past 10 year's average earnings per share (CAPE). With this the stock trades significantly higher than the average US stock of the food & drug retailers which now costs 31 times the average 10-years EPS.

Core figures US food & drug retailers

equity research

We further see that over the past year the American food & drug retailers yielded 3 percent higher. They performed worse than the European sector that yielded 3 percent higher. The American sector trades with a CAPE-ratio of 36 and the European sector trades at 22. The CAPE-ratios level doesn't seemt to have a relation with the price returns as the higher returns don't all have higher CAPE-ratios.

For this year Dominos Pizza's revenue will be around 3,45 billion USD. This is according to the average of the analysts' estimates. This is rather significant more than 2017's revenue of 2,79 billion USD.

Historical revenues and results Dominos Pizza plus estimates 2018

stock analysis

The analysts expect for 2018 a net profit of 368 million USD. For this year the consensus of Dominos Pizza's result per share is a profit of 8,47 USD. The price-earnings-ratio equals 31,12.

For this year the analysts expect a dividend of 2,15 USD per share. Thus the dividend yield equals 0,82 percent. The average dividend yield of the food & drug retailers equals a limited 1 percent.

Based on the current number of outstanding shares Dominos Pizza's market capitalization is 12,68 billion USD. The Dominos Pizza stock was the past 12 months quite unstable. Since last November the stock is even 56 percent higher. This year the stock price moved between 167 and 305 dollar. Since 2008 the stock price is almost 5129 percent higher.

Price data Dominos Pizza 2007-2018

stock analysis dominospizza

On Tuesday the stock closed at 263,56 USD. News Wire & Equity Research: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.